Ann: US CPT Code Reimbursement for TALi Detect, page-427

For calculating annual potential market size, I think only annual newborn figure is relevant unless requiring repeating screening tests for more than one year.

Agree Nhl still has a lot of work to do, It's speculative at current stage despite having RECEIVED FDA approval, CE mark and TGA approval for TALi Train. That's probably why it is just valued at $30m.

Just for exercise, PCK, pain assessment app, received Ce mark in 2017, annual revenue 122k, share price remained at low until six months ago, but suddenly it rose to 30c, Disallowed, with $288m market cap, June quarter revenue $22k. Still waiting for FDA approval.

Nhl, has FDA approvec TALi Train, still has TALi Detect.

It might be only worthy $10m, or more, no one would know.